O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
2008
Purpose of the study In the randomised, controlled, Phase III TITAN trial, at week 96, significantly more patients on darunavir coadministered with low-dose ritonavir (DRV/r) than on lopinavir/r (LPV/r) achieved HIV-1 RNA <400 copies/mL (67.5% vs. 59.5%; difference 8%, 95% CI 0.1–15.8), confirming non-inferiority (p < 0.001) and superiority of DRV/r over LPV/r (p = 0.034). A detailed resistance characterisation of virological failures (VFs) was performed.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI